IAGX: AI 评分 47/100 — AI 分析 (4月 2026)

Imagenetix, Inc. develops and markets natural-based nutritional supplements and over-the-counter topical creams, with a focus on its primary product, Celadrin, for joint health. The company distributes its products through various channels and licenses its intellectual property.

Key Facts: AI Score: 47/100 Sector: Healthcare

公司概况

概要：

Imagenetix, Inc. is a healthcare company focused on developing, formulating, and marketing proprietary and natural-based nutritional supplements, primarily Celadrin for joint health. The company operates within the specialty and generic drug manufacturing sector, distributing products through diverse channels and licensing its intellectual property.

IAGX是做什么的？

Founded in 1996 and based in San Diego, California, Imagenetix, Inc. operates within the healthcare sector, specifically in the realm of specialty and generic drug manufacturing. The company develops, formulates, and markets a range of proprietary and natural-based nutritional supplements, over-the-counter topical creams, and skincare products. Its flagship product, Celadrin, is a formulation designed to support joint health. In addition to its own product lines, Imagenetix, Inc. also generates revenue through licensing its intellectual property to third parties. The company employs a multi-channel distribution strategy, leveraging direct and mass marketing companies, nutritional and medical newsletters, and direct response radio and television to reach its target market. Imagenetix aims to provide consumers with natural alternatives for health and wellness, focusing on product efficacy and market accessibility. The company's size is relatively small, with only 5 employees, reflecting its focus on niche markets and specialized product offerings.

IAGX的投资论点是什么？

Imagenetix, Inc. presents a unique investment profile within the specialty and generic drug manufacturing sector. The company's focus on natural-based nutritional supplements and over-the-counter products, particularly Celadrin, caters to the growing demand for alternative healthcare solutions. With a market capitalization of $0.00 billion and a negative P/E ratio of -0.13, the company's financial performance indicates potential challenges. However, a gross margin of 41.6% suggests a viable product portfolio. Growth catalysts include expanding distribution channels and strategic licensing agreements. Potential risks involve the company's small size, limited financial resources, and the highly competitive nature of the healthcare industry. The company's beta of -406.06 suggests an inverse correlation with the market.

IAGX在哪个行业运营？

Imagenetix, Inc. operates in the competitive specialty and generic drug manufacturing industry, which is characterized by increasing demand for over-the-counter and natural health products. The global nutritional supplements market is projected to reach billions of dollars by 2026, driven by rising health awareness and an aging population. Key competitors include both large pharmaceutical companies and smaller niche players. Imagenetix differentiates itself through its focus on proprietary formulations and natural ingredients, targeting consumers seeking alternative healthcare solutions. The company's success depends on its ability to innovate, effectively market its products, and navigate the complex regulatory landscape.

Drug Manufacturers - Specialty & Generic

Healthcare

IAGX有哪些增长机遇？

Expansion of Distribution Channels: Imagenetix can increase its market reach by expanding its distribution channels to include online retailers, pharmacies, and international markets. The global e-commerce market for health and personal care products is experiencing rapid growth, offering a significant opportunity for Imagenetix to increase sales and brand awareness. By leveraging online platforms and strategic partnerships, the company can tap into new customer segments and drive revenue growth. Timeline: Within the next 2 years.
Strategic Licensing Agreements: Imagenetix can leverage its intellectual property by entering into strategic licensing agreements with other companies in the healthcare and wellness industry. Licensing agreements can provide a recurring revenue stream and expand the reach of Celadrin and other proprietary formulations. The market for licensing agreements in the healthcare sector is substantial, with numerous opportunities for companies with innovative products and technologies. Timeline: Ongoing.
New Product Development: Imagenetix can drive growth by developing new products that address unmet needs in the healthcare market. The company can leverage its expertise in natural-based formulations to create innovative supplements and topical creams for various health conditions. The market for new and innovative healthcare products is constantly evolving, with consumers seeking effective and natural solutions for their health concerns. Timeline: Within the next 3 years.
Targeted Marketing Campaigns: Imagenetix can enhance its brand awareness and drive sales through targeted marketing campaigns that focus on the benefits of Celadrin and other products. The company can leverage digital marketing channels, such as social media and search engine optimization, to reach its target audience and promote its products. The effectiveness of marketing campaigns can be measured through key performance indicators, such as website traffic, lead generation, and sales conversions. Timeline: Ongoing.
International Expansion: Imagenetix can expand its market presence by entering new international markets. The global market for nutritional supplements and over-the-counter products is vast, with significant opportunities in emerging markets. By adapting its products and marketing strategies to local market conditions, Imagenetix can tap into new customer segments and drive revenue growth. Timeline: Within the next 5 years.

Gross Margin of 41.6% indicates potential profitability in product sales.
Market Cap of $0.00B reflects the company's small size and limited market presence.
Profit Margin of -2.6% suggests the company is currently operating at a loss.
P/E Ratio of -0.13 indicates negative earnings, making valuation challenging.
Beta of -406.06 suggests an inverse correlation with the market, potentially offering diversification benefits.

IAGX提供哪些产品和服务？

Develops proprietary nutritional supplements.
Formulates natural-based health products.
Markets over-the-counter topical creams.
Specializes in skin care products.
Offers Celadrin for joint health.
Licenses intellectual property to third parties.

IAGX如何赚钱？

Develops and manufactures proprietary health products.
Markets products through various distribution channels.
Generates revenue through product sales.
Licenses intellectual property for additional income.

Individuals seeking joint health solutions.
Consumers interested in natural nutritional supplements.
Customers of direct and mass marketing companies.
Readers of nutritional and medical newsletters.

Proprietary product formulations.
Established brand recognition for Celadrin.
Multi-channel distribution network.
Intellectual property licensing agreements.

什么因素可能推动IAGX股价上涨？

Upcoming: Potential new licensing agreements for Celadrin.
Ongoing: Expansion of online distribution channels.
Upcoming: Launch of new product formulations.
Ongoing: Increased marketing efforts to drive brand awareness.

IAGX的主要风险是什么？

Potential: Limited financial resources may hinder growth initiatives.
Ongoing: Intense competition in the healthcare industry.
Potential: Regulatory changes affecting the supplement industry.
Ongoing: Dependence on a limited product portfolio.
Potential: Product liability claims.

IAGX的核心优势是什么？

Proprietary product formulations (e.g., Celadrin).
Established distribution network.
Focus on natural-based products.
Intellectual property licensing opportunities.

IAGX的劣势是什么？

Small company size and limited resources.
Negative profit margin.
High beta value indicating volatility.
Dependence on a limited product portfolio.

IAGX有哪些机遇？

Expansion into new markets and distribution channels.
Development of new products and formulations.
Strategic partnerships and licensing agreements.
Growing demand for natural health products.

IAGX面临哪些威胁？

Intense competition in the healthcare industry.
Regulatory changes and compliance requirements.
Potential product liability claims.
Economic downturns affecting consumer spending.

IAGX的竞争对手是谁？

Biozoom Inc — Focuses on health and wellness technologies. — (BZAMF)
CannAssist Wellness Corp — Develops and markets cannabis-based wellness products. — (CANQF)
CV Holdings, Inc. — Operates in the healthcare and financial services sectors. — (CVHIF)
Guggenheim Build America Mutual — Fixed income investments. — (GBIM)
NIVALIS THERAPEUTICS — Focuses on developing therapies for genetic diseases. — (NLVVF)

Key Metrics

MoonshotScore: 47/100

Company Profile

CEO: Decky Goodrich
Headquarters: San Diego, US
Employees: 5
Founded: 2000

AI Insight

AI analysis pending for IAGX

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Imagenetix, Inc. do?

Imagenetix, Inc. is a healthcare company that develops, formulates, and markets proprietary and natural-based nutritional supplements, over-the-counter topical creams, and skincare products. Its primary product is Celadrin, a formulation for joint health. The company distributes its products through various channels, including direct marketing, newsletters, and medical professionals. Additionally, Imagenetix licenses its intellectual property to third parties, generating revenue through both product sales and licensing agreements. The company focuses on providing natural alternatives for health and wellness, targeting consumers seeking specialized health solutions.

What revenue streams does Imagenetix, Inc. have in healthcare?

Imagenetix, Inc.'s revenue streams primarily come from the sale of its proprietary and natural-based nutritional supplements and over-the-counter products, with Celadrin being a key contributor. Revenue is generated through various distribution channels, including direct and mass marketing companies, nutritional newsletters, and medical professionals. Additionally, the company earns revenue by licensing its intellectual property to third parties. The specific breakdown of revenue by product line and channel is not publicly available, but Celadrin and licensing agreements are significant components.

What are the main risks for IAGX?

The main risks for Imagenetix, Inc. include its small size and limited financial resources, which may hinder its ability to compete effectively in the healthcare industry. The company's negative profit margin indicates financial challenges, and its dependence on a limited product portfolio exposes it to market fluctuations. Additionally, regulatory changes in the supplement industry and potential product liability claims pose significant risks. As an OTC-listed company, IAGX faces additional risks related to liquidity, disclosure, and regulatory oversight.